179 related articles for article (PubMed ID: 38318175)
1. TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.
Schober SJ; Thiede M; Gassmann H; von Ofen AJ; Knoch P; Eck J; Prexler C; Kordass-Wally C; Hauer J; Burdach S; Holm PS; Thiel U
Front Immunol; 2024; 15():1330868. PubMed ID: 38318175
[TBL] [Abstract][Full Text] [Related]
2. The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma.
Schober SJ; Schoening C; Eck J; Middendorf C; Lutsch J; Knoch P; von Ofen AJ; Gassmann H; Thiede M; Hauer J; Kolk A; Mantwill K; Gschwend JE; Burdach SEG; Nawroth R; Thiel U; Holm PS
Clin Cancer Res; 2023 May; 29(10):1996-2011. PubMed ID: 36892582
[TBL] [Abstract][Full Text] [Related]
3. Monocyte Maturation Mediators Upregulate CD83, ICAM-1 and MHC Class 1 Expression on Ewing's Sarcoma, Enhancing T Cell Cytotoxicity.
Biele E; Schober SJ; Prexler C; Thiede M; Heyking KV; Gassmann H; Eck J; Xue B; Burdach S; Thiel U
Cells; 2021 Nov; 10(11):. PubMed ID: 34831294
[TBL] [Abstract][Full Text] [Related]
4. The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model.
Klawitter M; El-Ayoubi A; Buch J; Rüttinger J; Ehrenfeld M; Lichtenegger E; Krüger MA; Mantwill K; Koll FJ; Kowarik MC; Holm PS; Naumann U
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077380
[TBL] [Abstract][Full Text] [Related]
5. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.
Blaeschke F; Thiel U; Kirschner A; Thiede M; Rubio RA; Schirmer D; Kirchner T; Richter GHS; Mall S; Klar R; Riddell S; Busch DH; Krackhardt A; Grunewald TG; Burdach S
Oncotarget; 2016 Jul; 7(28):43267-43280. PubMed ID: 27281613
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
[TBL] [Abstract][Full Text] [Related]
7. Using targeted virotherapy to treat a resistant Ewing sarcoma model: from the bedside to the bench and back.
Abdelbary H; Brown CW; Werier J; Bell J
ScientificWorldJournal; 2014; 2014():171439. PubMed ID: 24672293
[TBL] [Abstract][Full Text] [Related]
8. MHC Class I-Restricted TCR-Transgenic CD4
Schober SJ; Thiede M; Gassmann H; Prexler C; Xue B; Schirmer D; Wohlleber D; Stein S; Grünewald TGP; Busch DH; Richter GHS; Burdach SEG; Thiel U
Cells; 2020 Jun; 9(7):. PubMed ID: 32610710
[TBL] [Abstract][Full Text] [Related]
9. YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells.
von Ofen AJ; Thiel U; Eck J; Gassmann H; Thiede M; Hauer J; Holm PS; Schober SJ
Front Oncol; 2024; 14():1304374. PubMed ID: 38357194
[TBL] [Abstract][Full Text] [Related]
10. EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.
Evans CH; Liu F; Porter RM; O'Sullivan RP; Merghoub T; Lunsford EP; Robichaud K; Van Valen F; Lessnick SL; Gebhardt MC; Wells JW
Clin Cancer Res; 2012 Oct; 18(19):5341-51. PubMed ID: 22879388
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
[TBL] [Abstract][Full Text] [Related]
12. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
13. Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease.
Ekeke CN; Russell KL; Murthy P; Guo ZS; Soloff AC; Weber D; Pan W; Lotze MT; Dhupar R
J Thorac Cardiovasc Surg; 2022 Apr; 163(4):e313-e328. PubMed ID: 33485667
[TBL] [Abstract][Full Text] [Related]
14. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
15. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment.
Denton NL; Chen CY; Hutzen B; Currier MA; Scott T; Nartker B; Leddon JL; Wang PY; Srinivas R; Cassady KA; Goins WF; Cripe TP
Mol Ther Oncolytics; 2018 Dec; 11():62-74. PubMed ID: 30505937
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
17. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
[TBL] [Abstract][Full Text] [Related]
18. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma.
Charan M; Dravid P; Cam M; Audino A; Gross AC; Arnold MA; Roberts RD; Cripe TP; Pertsemlidis A; Houghton PJ; Cam H
Int J Cancer; 2020 Jun; 146(11):3184-3195. PubMed ID: 31621900
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
20. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]